Report long-term 50 mg nomlabofusp data
Delivered after the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 16 Dec 2024
- Due
- 30 Jun 2025
- Delivered
- September 2025
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Long-term 50 mg data expected mid-2025”
What we found
Evidence strength A What the grades mean
The company announced in August 2025 that the planned update for the 50 mg dose data was scheduled for September 2025, missing the mid-2025 deadline.
-
A Larimar Therapeutics, Inc. 8-K filed 2025-08-14
“Initial data from the 50 mg dose in the open label study and the adolescent PK run-in study planned for program update in September 2025” ✓ confirmed on the page
-
A Larimar Therapeutics, Inc. 10-Q filed 2025-11-05
“In September 2025, the Company announced data from its ongoing long-term open label study” ✓ confirmed on the page
Market reaction: the shares moved +5.1% against the S&P 500 over the three sessions around the disclosure (13 Aug 2025 to 18 Aug 2025). What this measures
Checked 1 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Report
- Deliverable
- Long-term 50 mg nomlabofusp data
- Target
- 50 mg
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Larimar Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2024-LRMR-003021 · Corrections policy